Zymeworks Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss and Comprehensive Loss
(In thousands except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | ||
| Research and development collaborations | $2,408 | $27,110 |
| Operating expenses: | ||
| Research and development | 34,457 | 35,738 |
| General and administrative | 15,069 | 16,985 |
| Total operating expenses | 49,526 | 52,723 |
| Loss from operations | (47,118) | (25,613) |
| Other income: | ||
| Interest income | 2,711 | 3,424 |
| Interest expense related to sale of future royalties | (2,066) | — |
| Other income, net | 120 | 49 |
| Total other income, net | 765 | 3,473 |
| Loss before income taxes | (46,353) | (22,140) |
| Income tax recovery (expense) | 2,191 | (496) |
| Net loss | (44,162) | (22,636) |
| Other comprehensive income: | ||
| Unrealized (loss) income on available for sale securities, net of tax of $0 | (486) | 546 |
| Total other comprehensive (loss) income | (486) | 546 |
| Comprehensive loss | $(44,648) | $(22,090) |
| Net loss per common share: | ||
| Basic | $(0.59) | $(0.30) |
| Diluted | $(0.59) | $(0.30) |
| Weighted-average common stock outstanding: | ||
| Basic | 74,668,790 | 75,171,020 |
| Diluted | 74,694,762 | 75,226,387 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.